Cosmorobotics, a medical wearable rehabilitation robot specialist, surged 250% above its initial public offering price on its Kosdaq debut, tracking a quadruple-price move.
As of 9:15 a.m. on Nov. 11, Cosmorobotics was trading at 21,000 won, up 15,000 won, or 250%, from its IPO price. The company had set its offering price at 6,000 won, the top of the indicative range, in its institutional book-building last month. In the subsequent retail subscription, it drew around 6.3 trillion won in deposits, marking a successful debut.
Cosmorobotics manufactures and sells exoskeleton robots for the rehabilitation and walking assistance of patients with lower-limb paralysis. Under the motto of "warm technology," the company is targeting the medical wearable rehabilitation robot market.
Its main products are rehabilitation robots for adults and for children and adolescents. Adult products account for about 51% of total sales, while pediatric and adolescent products make up around 44%. Industry watchers say Cosmorobotics is the only company in the wearable rehabilitation robot market that has secured a full life-cycle lineup.
In particular, while competitors focus their businesses on the adult market, Cosmorobotics is rapidly expanding into the pediatric and adolescent market, a key point of differentiation.
Growth in the end markets is another positive factor. The global rehabilitation and wearable robot market is projected to grow at an average annual rate of around 37%. With aging populations and rising numbers of patients with gait disorders such as stroke and Parkinson's disease, demand for robot-based rehabilitation solutions is also expanding rapidly.
Cosmorobotics is currently expanding its business in major overseas markets including the United States, Japan, Europe and China. As of this year, exports account for about 86% of its revenue. In particular, the company is targeting the U.S. pediatric home-use market as a new growth driver and is pushing into the business-to-consumer (B2C) market beyond business-to-business (B2B).
"Cosmorobotics is a proven exporter, and key certification events essential for expanding exports are concentrated in 2026 and 2027, providing a clear growth road map with specific schedules," said Lee Gun-jae, an analyst at IBK Investment & Securities. "As a company listing on the Kosdaq under the technology special listing track, there are still shortcomings in profitability, but it appears likely to swiftly turn to the black."
Subscription ratio hits 1,140:1! Can Cosmorobotics' 6,000-won IPO quadruple?
